Baird Medical Investment Holdings Limited
Get $10 bonus on your first $100 deposit for BDMD
Get $10 bonus on your first $100 deposit for BDMD
Baird Medical Investment Holdings Limited (BDMD) Stock Competitors & Peer Comparison
See (BDMD) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BDMD | $1.77 | -1.12% | 66.5M | -16.45 | -$0.11 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $92.72 | -3.42% | 161.2B | 25.98 | $3.57 | +1.36% |
| SYK | $327.30 | -3.26% | 125.4B | 38.92 | $8.41 | +1.05% |
| MDT | $82.00 | -3.53% | 105.3B | 22.91 | $3.58 | +1.72% |
| BSX | $59.52 | -2.41% | 88.4B | 30.66 | $1.94 | N/A |
| BRKRP | $319.35 | -0.25% | 47.7B | N/A | N/A | +0.25% |
| EW | $79.71 | -2.12% | 46.3B | 44.05 | $1.81 | N/A |
| PHG | $28.48 | -2.43% | 27.3B | 25.89 | $1.10 | +3.38% |
| DXCM | $62.60 | -3.13% | 24.4B | 29.95 | $2.09 | N/A |
Stock Comparison
BDMD vs BSX-PA Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, BDMD is priced at $1.77, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, BDMD's ROE is -0.08%, compared to BSX-PA's ROE of +0.13%. Regarding short-term risk, BDMD is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check BSX-PA's competition here
BDMD vs ABT Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, ABT has a market cap of 161.2B. Regarding current trading prices, BDMD is priced at $1.77, while ABT trades at $92.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas ABT's P/E ratio is 25.98. In terms of profitability, BDMD's ROE is -0.08%, compared to ABT's ROE of +0.12%. Regarding short-term risk, BDMD is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check ABT's competition here
BDMD vs SYK Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, SYK has a market cap of 125.4B. Regarding current trading prices, BDMD is priced at $1.77, while SYK trades at $327.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas SYK's P/E ratio is 38.92. In terms of profitability, BDMD's ROE is -0.08%, compared to SYK's ROE of +0.15%. Regarding short-term risk, BDMD is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check SYK's competition here
BDMD vs MDT Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, MDT has a market cap of 105.3B. Regarding current trading prices, BDMD is priced at $1.77, while MDT trades at $82.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas MDT's P/E ratio is 22.91. In terms of profitability, BDMD's ROE is -0.08%, compared to MDT's ROE of +0.10%. Regarding short-term risk, BDMD is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check MDT's competition here
BDMD vs BSX Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, BSX has a market cap of 88.4B. Regarding current trading prices, BDMD is priced at $1.77, while BSX trades at $59.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas BSX's P/E ratio is 30.66. In terms of profitability, BDMD's ROE is -0.08%, compared to BSX's ROE of +0.13%. Regarding short-term risk, BDMD is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check BSX's competition here
BDMD vs BRKRP Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, BRKRP has a market cap of 47.7B. Regarding current trading prices, BDMD is priced at $1.77, while BRKRP trades at $319.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas BRKRP's P/E ratio is N/A. In terms of profitability, BDMD's ROE is -0.08%, compared to BRKRP's ROE of -0.00%. Regarding short-term risk, BDMD is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check BRKRP's competition here
BDMD vs EW Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, EW has a market cap of 46.3B. Regarding current trading prices, BDMD is priced at $1.77, while EW trades at $79.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas EW's P/E ratio is 44.05. In terms of profitability, BDMD's ROE is -0.08%, compared to EW's ROE of +0.10%. Regarding short-term risk, BDMD is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check EW's competition here
BDMD vs PHG Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, PHG has a market cap of 27.3B. Regarding current trading prices, BDMD is priced at $1.77, while PHG trades at $28.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas PHG's P/E ratio is 25.89. In terms of profitability, BDMD's ROE is -0.08%, compared to PHG's ROE of +0.08%. Regarding short-term risk, BDMD is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check PHG's competition here
BDMD vs DXCM Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, DXCM has a market cap of 24.4B. Regarding current trading prices, BDMD is priced at $1.77, while DXCM trades at $62.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas DXCM's P/E ratio is 29.95. In terms of profitability, BDMD's ROE is -0.08%, compared to DXCM's ROE of +0.32%. Regarding short-term risk, BDMD is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check DXCM's competition here
BDMD vs STE Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, STE has a market cap of 21.5B. Regarding current trading prices, BDMD is priced at $1.77, while STE trades at $219.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas STE's P/E ratio is 30.59. In terms of profitability, BDMD's ROE is -0.08%, compared to STE's ROE of +0.10%. Regarding short-term risk, BDMD is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check STE's competition here
BDMD vs ZBH Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, ZBH has a market cap of 18.1B. Regarding current trading prices, BDMD is priced at $1.77, while ZBH trades at $92.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas ZBH's P/E ratio is 26.11. In terms of profitability, BDMD's ROE is -0.08%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, BDMD is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check ZBH's competition here
BDMD vs ABMD Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, BDMD is priced at $1.77, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas ABMD's P/E ratio is 65.36. In terms of profitability, BDMD's ROE is -0.08%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, BDMD is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check ABMD's competition here
BDMD vs SNN Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, SNN has a market cap of 14B. Regarding current trading prices, BDMD is priced at $1.77, while SNN trades at $32.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas SNN's P/E ratio is 22.96. In terms of profitability, BDMD's ROE is -0.08%, compared to SNN's ROE of +0.12%. Regarding short-term risk, BDMD is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check SNN's competition here
BDMD vs ALGN Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, ALGN has a market cap of 14B. Regarding current trading prices, BDMD is priced at $1.77, while ALGN trades at $195.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas ALGN's P/E ratio is 34.56. In terms of profitability, BDMD's ROE is -0.08%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, BDMD is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check ALGN's competition here
BDMD vs PODD Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, PODD has a market cap of 13.5B. Regarding current trading prices, BDMD is priced at $1.77, while PODD trades at $192.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas PODD's P/E ratio is 55.27. In terms of profitability, BDMD's ROE is -0.08%, compared to PODD's ROE of +0.17%. Regarding short-term risk, BDMD is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check PODD's competition here
BDMD vs PEN Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, PEN has a market cap of 12.9B. Regarding current trading prices, BDMD is priced at $1.77, while PEN trades at $327.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas PEN's P/E ratio is 72.46. In terms of profitability, BDMD's ROE is -0.08%, compared to PEN's ROE of +0.13%. Regarding short-term risk, BDMD is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check PEN's competition here
BDMD vs GMED Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, GMED has a market cap of 12.7B. Regarding current trading prices, BDMD is priced at $1.77, while GMED trades at $93.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas GMED's P/E ratio is 23.93. In terms of profitability, BDMD's ROE is -0.08%, compared to GMED's ROE of +0.12%. Regarding short-term risk, BDMD is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check GMED's competition here
BDMD vs SWAV Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, BDMD is priced at $1.77, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas SWAV's P/E ratio is 78.76. In terms of profitability, BDMD's ROE is -0.08%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, BDMD is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check SWAV's competition here
BDMD vs BIO Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, BIO has a market cap of 8.3B. Regarding current trading prices, BDMD is priced at $1.77, while BIO trades at $305.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas BIO's P/E ratio is 10.97. In terms of profitability, BDMD's ROE is -0.08%, compared to BIO's ROE of +0.11%. Regarding short-term risk, BDMD is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check BIO's competition here
BDMD vs BIO-B Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, BIO-B has a market cap of 8.2B. Regarding current trading prices, BDMD is priced at $1.77, while BIO-B trades at $277.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas BIO-B's P/E ratio is 10.84. In terms of profitability, BDMD's ROE is -0.08%, compared to BIO-B's ROE of +0.11%. Regarding short-term risk, BDMD is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check BIO-B's competition here
BDMD vs GKOS Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, GKOS has a market cap of 7.1B. Regarding current trading prices, BDMD is priced at $1.77, while GKOS trades at $122.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas GKOS's P/E ratio is -37.21. In terms of profitability, BDMD's ROE is -0.08%, compared to GKOS's ROE of -0.25%. Regarding short-term risk, BDMD is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check GKOS's competition here
BDMD vs BRKR Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, BRKR has a market cap of 6.1B. Regarding current trading prices, BDMD is priced at $1.77, while BRKR trades at $40.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas BRKR's P/E ratio is -267.27. In terms of profitability, BDMD's ROE is -0.08%, compared to BRKR's ROE of -0.00%. Regarding short-term risk, BDMD is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check BRKR's competition here
BDMD vs NARI Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, BDMD is priced at $1.77, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas NARI's P/E ratio is -59.24. In terms of profitability, BDMD's ROE is -0.08%, compared to NARI's ROE of -0.00%. Regarding short-term risk, BDMD is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check NARI's competition here
BDMD vs IRTC Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, IRTC has a market cap of 3.8B. Regarding current trading prices, BDMD is priced at $1.77, while IRTC trades at $118.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas IRTC's P/E ratio is -85.53. In terms of profitability, BDMD's ROE is -0.08%, compared to IRTC's ROE of -0.38%. Regarding short-term risk, BDMD is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check IRTC's competition here
BDMD vs TMDX Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, TMDX has a market cap of 3.7B. Regarding current trading prices, BDMD is priced at $1.77, while TMDX trades at $108.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas TMDX's P/E ratio is 22.36. In terms of profitability, BDMD's ROE is -0.08%, compared to TMDX's ROE of +0.54%. Regarding short-term risk, BDMD is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check TMDX's competition here
BDMD vs AXNX Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, BDMD is priced at $1.77, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas AXNX's P/E ratio is -709.80. In terms of profitability, BDMD's ROE is -0.08%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, BDMD is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check AXNX's competition here
BDMD vs LIVN Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, LIVN has a market cap of 3.5B. Regarding current trading prices, BDMD is priced at $1.77, while LIVN trades at $64.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas LIVN's P/E ratio is -14.50. In terms of profitability, BDMD's ROE is -0.08%, compared to LIVN's ROE of -0.21%. Regarding short-term risk, BDMD is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check LIVN's competition here
BDMD vs ITGR Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, ITGR has a market cap of 2.9B. Regarding current trading prices, BDMD is priced at $1.77, while ITGR trades at $85.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas ITGR's P/E ratio is 29.62. In terms of profitability, BDMD's ROE is -0.08%, compared to ITGR's ROE of +0.06%. Regarding short-term risk, BDMD is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check ITGR's competition here
BDMD vs NUVA Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, BDMD is priced at $1.77, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas NUVA's P/E ratio is 75.00. In terms of profitability, BDMD's ROE is -0.08%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, BDMD is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check NUVA's competition here
BDMD vs ESTA Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, ESTA has a market cap of 1.9B. Regarding current trading prices, BDMD is priced at $1.77, while ESTA trades at $64.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas ESTA's P/E ratio is -37.24. In terms of profitability, BDMD's ROE is -0.08%, compared to ESTA's ROE of -2.02%. Regarding short-term risk, BDMD is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check ESTA's competition here
BDMD vs AXGN Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, AXGN has a market cap of 1.9B. Regarding current trading prices, BDMD is priced at $1.77, while AXGN trades at $35.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas AXGN's P/E ratio is -105.53. In terms of profitability, BDMD's ROE is -0.08%, compared to AXGN's ROE of -0.13%. Regarding short-term risk, BDMD is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check AXGN's competition here
BDMD vs AORT Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, AORT has a market cap of 1.8B. Regarding current trading prices, BDMD is priced at $1.77, while AORT trades at $36.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas AORT's P/E ratio is 174.29. In terms of profitability, BDMD's ROE is -0.08%, compared to AORT's ROE of +0.02%. Regarding short-term risk, BDMD is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for BDMD.Check AORT's competition here
BDMD vs AHCO Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, AHCO has a market cap of 1.7B. Regarding current trading prices, BDMD is priced at $1.77, while AHCO trades at $12.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas AHCO's P/E ratio is -23.36. In terms of profitability, BDMD's ROE is -0.08%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, BDMD is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check AHCO's competition here
BDMD vs ATEC Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, BDMD is priced at $1.77, while ATEC trades at $10.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas ATEC's P/E ratio is -10.91. In terms of profitability, BDMD's ROE is -0.08%, compared to ATEC's ROE of -17.60%. Regarding short-term risk, BDMD is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for BDMD.Check ATEC's competition here
BDMD vs UFPT Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, UFPT has a market cap of 1.5B. Regarding current trading prices, BDMD is priced at $1.77, while UFPT trades at $198.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas UFPT's P/E ratio is 22.69. In terms of profitability, BDMD's ROE is -0.08%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, BDMD is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check UFPT's competition here
BDMD vs INSP Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, INSP has a market cap of 1.5B. Regarding current trading prices, BDMD is priced at $1.77, while INSP trades at $52.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas INSP's P/E ratio is 10.64. In terms of profitability, BDMD's ROE is -0.08%, compared to INSP's ROE of +0.21%. Regarding short-term risk, BDMD is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for BDMD.Check INSP's competition here
BDMD vs PRCT Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, PRCT has a market cap of 1.4B. Regarding current trading prices, BDMD is priced at $1.77, while PRCT trades at $24.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas PRCT's P/E ratio is -14.07. In terms of profitability, BDMD's ROE is -0.08%, compared to PRCT's ROE of -0.25%. Regarding short-term risk, BDMD is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check PRCT's competition here
BDMD vs BFLY Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, BFLY has a market cap of 1.4B. Regarding current trading prices, BDMD is priced at $1.77, while BFLY trades at $5.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas BFLY's P/E ratio is -17.58. In terms of profitability, BDMD's ROE is -0.08%, compared to BFLY's ROE of -0.35%. Regarding short-term risk, BDMD is more volatile compared to BFLY. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check BFLY's competition here
BDMD vs TNDM Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, TNDM has a market cap of 1.4B. Regarding current trading prices, BDMD is priced at $1.77, while TNDM trades at $20.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas TNDM's P/E ratio is -6.59. In terms of profitability, BDMD's ROE is -0.08%, compared to TNDM's ROE of -1.42%. Regarding short-term risk, BDMD is more volatile compared to TNDM. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check TNDM's competition here
BDMD vs PMI Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, PMI has a market cap of 1.3B. Regarding current trading prices, BDMD is priced at $1.77, while PMI trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas PMI's P/E ratio is -1.15. In terms of profitability, BDMD's ROE is -0.08%, compared to PMI's ROE of +2.17%. Regarding short-term risk, BDMD is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for BDMD.Check PMI's competition here
BDMD vs HSKA Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, BDMD is priced at $1.77, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas HSKA's P/E ratio is -62.49. In terms of profitability, BDMD's ROE is -0.08%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, BDMD is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check HSKA's competition here
BDMD vs CNMD Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, CNMD has a market cap of 1.2B. Regarding current trading prices, BDMD is priced at $1.77, while CNMD trades at $38.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas CNMD's P/E ratio is 25.44. In terms of profitability, BDMD's ROE is -0.08%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, BDMD is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check CNMD's competition here
BDMD vs AVNS Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, BDMD is priced at $1.77, while AVNS trades at $24.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas AVNS's P/E ratio is -15.69. In terms of profitability, BDMD's ROE is -0.08%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, BDMD is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check AVNS's competition here
BDMD vs IRMD Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, BDMD is priced at $1.77, while IRMD trades at $89.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas IRMD's P/E ratio is 51.02. In terms of profitability, BDMD's ROE is -0.08%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, BDMD is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check IRMD's competition here
BDMD vs SILK Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, BDMD is priced at $1.77, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas SILK's P/E ratio is -18.96. In terms of profitability, BDMD's ROE is -0.08%, compared to SILK's ROE of -0.35%. Regarding short-term risk, BDMD is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check SILK's competition here
BDMD vs FNA Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, BDMD is priced at $1.77, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas FNA's P/E ratio is -19.83. In terms of profitability, BDMD's ROE is -0.08%, compared to FNA's ROE of -0.35%. Regarding short-term risk, BDMD is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check FNA's competition here
BDMD vs SSII Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, SSII has a market cap of 920.6M. Regarding current trading prices, BDMD is priced at $1.77, while SSII trades at $4.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas SSII's P/E ratio is -76.67. In terms of profitability, BDMD's ROE is -0.08%, compared to SSII's ROE of -0.30%. Regarding short-term risk, BDMD is more volatile compared to SSII. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check SSII's competition here
BDMD vs INMD Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, INMD has a market cap of 919.3M. Regarding current trading prices, BDMD is priced at $1.77, while INMD trades at $14.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas INMD's P/E ratio is 10.15. In terms of profitability, BDMD's ROE is -0.08%, compared to INMD's ROE of +0.15%. Regarding short-term risk, BDMD is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check INMD's competition here
BDMD vs LMRI Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, LMRI has a market cap of 895.7M. Regarding current trading prices, BDMD is priced at $1.77, while LMRI trades at $9.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas LMRI's P/E ratio is -14.12. In terms of profitability, BDMD's ROE is -0.08%, compared to LMRI's ROE of -0.18%. Regarding short-term risk, BDMD is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for BDMD.Check LMRI's competition here
BDMD vs CSII Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, BDMD is priced at $1.77, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas CSII's P/E ratio is -20.83. In terms of profitability, BDMD's ROE is -0.08%, compared to CSII's ROE of -0.14%. Regarding short-term risk, BDMD is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check CSII's competition here
BDMD vs IART Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, IART has a market cap of 819.9M. Regarding current trading prices, BDMD is priced at $1.77, while IART trades at $10.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas IART's P/E ratio is -1.56. In terms of profitability, BDMD's ROE is -0.08%, compared to IART's ROE of -0.44%. Regarding short-term risk, BDMD is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check IART's competition here
BDMD vs CBLL Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, CBLL has a market cap of 788.2M. Regarding current trading prices, BDMD is priced at $1.77, while CBLL trades at $20.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas CBLL's P/E ratio is -14.34. In terms of profitability, BDMD's ROE is -0.08%, compared to CBLL's ROE of -0.32%. Regarding short-term risk, BDMD is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check CBLL's competition here
BDMD vs CRY Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, BDMD is priced at $1.77, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas CRY's P/E ratio is 425.71. In terms of profitability, BDMD's ROE is -0.08%, compared to CRY's ROE of +0.02%. Regarding short-term risk, BDMD is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check CRY's competition here
BDMD vs BVS Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, BVS has a market cap of 649.4M. Regarding current trading prices, BDMD is priced at $1.77, while BVS trades at $9.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas BVS's P/E ratio is 29.21. In terms of profitability, BDMD's ROE is -0.08%, compared to BVS's ROE of +0.14%. Regarding short-term risk, BDMD is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check BVS's competition here
BDMD vs SRDX Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, BDMD is priced at $1.77, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas SRDX's P/E ratio is -34.66. In terms of profitability, BDMD's ROE is -0.08%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, BDMD is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check SRDX's competition here
BDMD vs SIBN Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, SIBN has a market cap of 610.4M. Regarding current trading prices, BDMD is priced at $1.77, while SIBN trades at $13.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas SIBN's P/E ratio is -31.41. In terms of profitability, BDMD's ROE is -0.08%, compared to SIBN's ROE of -0.11%. Regarding short-term risk, BDMD is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check SIBN's competition here
BDMD vs BWAY Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, BWAY has a market cap of 600.9M. Regarding current trading prices, BDMD is priced at $1.77, while BWAY trades at $15.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas BWAY's P/E ratio is 85.11. In terms of profitability, BDMD's ROE is -0.08%, compared to BWAY's ROE of +0.11%. Regarding short-term risk, BDMD is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check BWAY's competition here
BDMD vs CTKB Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, CTKB has a market cap of 595.2M. Regarding current trading prices, BDMD is priced at $1.77, while CTKB trades at $4.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas CTKB's P/E ratio is -8.90. In terms of profitability, BDMD's ROE is -0.08%, compared to CTKB's ROE of -0.18%. Regarding short-term risk, BDMD is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check CTKB's competition here
BDMD vs APEN Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, BDMD is priced at $1.77, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas APEN's P/E ratio is -9.43. In terms of profitability, BDMD's ROE is -0.08%, compared to APEN's ROE of -0.85%. Regarding short-term risk, BDMD is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check APEN's competition here
BDMD vs TCMD Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, TCMD has a market cap of 564.2M. Regarding current trading prices, BDMD is priced at $1.77, while TCMD trades at $24.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas TCMD's P/E ratio is 30.24. In terms of profitability, BDMD's ROE is -0.08%, compared to TCMD's ROE of +0.09%. Regarding short-term risk, BDMD is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check TCMD's competition here
BDMD vs NPCE Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, NPCE has a market cap of 551.1M. Regarding current trading prices, BDMD is priced at $1.77, while NPCE trades at $16.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas NPCE's P/E ratio is -24.80. In terms of profitability, BDMD's ROE is -0.08%, compared to NPCE's ROE of -1.06%. Regarding short-term risk, BDMD is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check NPCE's competition here
BDMD vs ZIMV Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, BDMD is priced at $1.77, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, BDMD's ROE is -0.08%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, BDMD is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check ZIMV's competition here
BDMD vs PACB Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, PACB has a market cap of 519.4M. Regarding current trading prices, BDMD is priced at $1.77, while PACB trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas PACB's P/E ratio is -0.95. In terms of profitability, BDMD's ROE is -0.08%, compared to PACB's ROE of -11.23%. Regarding short-term risk, BDMD is more volatile compared to PACB. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check PACB's competition here
BDMD vs VREX Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, VREX has a market cap of 503M. Regarding current trading prices, BDMD is priced at $1.77, while VREX trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas VREX's P/E ratio is -7.32. In terms of profitability, BDMD's ROE is -0.08%, compared to VREX's ROE of -0.14%. Regarding short-term risk, BDMD is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check VREX's competition here
BDMD vs OFIX Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, OFIX has a market cap of 485.7M. Regarding current trading prices, BDMD is priced at $1.77, while OFIX trades at $12.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas OFIX's P/E ratio is -5.19. In terms of profitability, BDMD's ROE is -0.08%, compared to OFIX's ROE of -0.20%. Regarding short-term risk, BDMD is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check OFIX's competition here
BDMD vs KIDS Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, KIDS has a market cap of 410.8M. Regarding current trading prices, BDMD is priced at $1.77, while KIDS trades at $16.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas KIDS's P/E ratio is -9.62. In terms of profitability, BDMD's ROE is -0.08%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, BDMD is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check KIDS's competition here
BDMD vs LAB Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, LAB has a market cap of 373.8M. Regarding current trading prices, BDMD is priced at $1.77, while LAB trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas LAB's P/E ratio is -6.39. In terms of profitability, BDMD's ROE is -0.08%, compared to LAB's ROE of -0.18%. Regarding short-term risk, BDMD is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for BDMD.Check LAB's competition here
BDMD vs DCTH Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, DCTH has a market cap of 370.4M. Regarding current trading prices, BDMD is priced at $1.77, while DCTH trades at $10.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas DCTH's P/E ratio is 152.29. In terms of profitability, BDMD's ROE is -0.08%, compared to DCTH's ROE of +0.03%. Regarding short-term risk, BDMD is more volatile compared to DCTH. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check DCTH's competition here
BDMD vs CERS Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, CERS has a market cap of 369M. Regarding current trading prices, BDMD is priced at $1.77, while CERS trades at $1.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas CERS's P/E ratio is -24.00. In terms of profitability, BDMD's ROE is -0.08%, compared to CERS's ROE of -0.26%. Regarding short-term risk, BDMD is more volatile compared to CERS. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check CERS's competition here
BDMD vs VMD Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, VMD has a market cap of 357.5M. Regarding current trading prices, BDMD is priced at $1.77, while VMD trades at $9.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas VMD's P/E ratio is 25.03. In terms of profitability, BDMD's ROE is -0.08%, compared to VMD's ROE of +0.11%. Regarding short-term risk, BDMD is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check VMD's competition here
BDMD vs CATX Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, CATX has a market cap of 342.5M. Regarding current trading prices, BDMD is priced at $1.77, while CATX trades at $4.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas CATX's P/E ratio is -3.30. In terms of profitability, BDMD's ROE is -0.08%, compared to CATX's ROE of -0.41%. Regarding short-term risk, BDMD is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for BDMD.Check CATX's competition here
BDMD vs CLPT Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, CLPT has a market cap of 318.6M. Regarding current trading prices, BDMD is priced at $1.77, while CLPT trades at $10.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas CLPT's P/E ratio is -11.93. In terms of profitability, BDMD's ROE is -0.08%, compared to CLPT's ROE of -1.22%. Regarding short-term risk, BDMD is more volatile compared to CLPT. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check CLPT's competition here
BDMD vs SMLR Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, BDMD is priced at $1.77, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas SMLR's P/E ratio is 3.92. In terms of profitability, BDMD's ROE is -0.08%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, BDMD is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check SMLR's competition here
BDMD vs RXST Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, RXST has a market cap of 292.6M. Regarding current trading prices, BDMD is priced at $1.77, while RXST trades at $7.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas RXST's P/E ratio is -7.46. In terms of profitability, BDMD's ROE is -0.08%, compared to RXST's ROE of -0.14%. Regarding short-term risk, BDMD is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check RXST's competition here
BDMD vs SENS Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, SENS has a market cap of 281.3M. Regarding current trading prices, BDMD is priced at $1.77, while SENS trades at $6.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas SENS's P/E ratio is -4.05. In terms of profitability, BDMD's ROE is -0.08%, compared to SENS's ROE of -1.04%. Regarding short-term risk, BDMD is more volatile compared to SENS. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check SENS's competition here
BDMD vs MASS Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, MASS has a market cap of 271.4M. Regarding current trading prices, BDMD is priced at $1.77, while MASS trades at $7.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas MASS's P/E ratio is -7.81. In terms of profitability, BDMD's ROE is -0.08%, compared to MASS's ROE of +0.13%. Regarding short-term risk, BDMD is more volatile compared to MASS. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check MASS's competition here
BDMD vs MGRM Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, BDMD is priced at $1.77, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas MGRM's P/E ratio is -11.11. In terms of profitability, BDMD's ROE is -0.08%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, BDMD is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check MGRM's competition here
BDMD vs SGHT Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, SGHT has a market cap of 229.5M. Regarding current trading prices, BDMD is priced at $1.77, while SGHT trades at $4.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas SGHT's P/E ratio is -5.74. In terms of profitability, BDMD's ROE is -0.08%, compared to SGHT's ROE of -0.56%. Regarding short-term risk, BDMD is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check SGHT's competition here
BDMD vs NVRO Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, BDMD is priced at $1.77, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas NVRO's P/E ratio is -1.91. In terms of profitability, BDMD's ROE is -0.08%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, BDMD is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check NVRO's competition here
BDMD vs ANIK Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, ANIK has a market cap of 217.2M. Regarding current trading prices, BDMD is priced at $1.77, while ANIK trades at $15.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas ANIK's P/E ratio is -21.51. In terms of profitability, BDMD's ROE is -0.08%, compared to ANIK's ROE of -0.07%. Regarding short-term risk, BDMD is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check ANIK's competition here
BDMD vs EYES Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, BDMD is priced at $1.77, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas EYES's P/E ratio is N/A. In terms of profitability, BDMD's ROE is -0.08%, compared to EYES's ROE of -3.17%. Regarding short-term risk, BDMD is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check EYES's competition here
BDMD vs ELMD Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, ELMD has a market cap of 209.8M. Regarding current trading prices, BDMD is priced at $1.77, while ELMD trades at $25.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas ELMD's P/E ratio is 24.42. In terms of profitability, BDMD's ROE is -0.08%, compared to ELMD's ROE of +0.20%. Regarding short-term risk, BDMD is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check ELMD's competition here
BDMD vs AVR Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, AVR has a market cap of 209.7M. Regarding current trading prices, BDMD is priced at $1.77, while AVR trades at $5.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas AVR's P/E ratio is -2.24. In terms of profitability, BDMD's ROE is -0.08%, compared to AVR's ROE of -5.28%. Regarding short-term risk, BDMD is more volatile compared to AVR. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check AVR's competition here
BDMD vs PROF Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, PROF has a market cap of 207M. Regarding current trading prices, BDMD is priced at $1.77, while PROF trades at $6.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas PROF's P/E ratio is -4.85. In terms of profitability, BDMD's ROE is -0.08%, compared to PROF's ROE of -0.80%. Regarding short-term risk, BDMD is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check PROF's competition here
BDMD vs CVRX Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, CVRX has a market cap of 199.7M. Regarding current trading prices, BDMD is priced at $1.77, while CVRX trades at $7.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas CVRX's P/E ratio is -3.72. In terms of profitability, BDMD's ROE is -0.08%, compared to CVRX's ROE of -0.99%. Regarding short-term risk, BDMD is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for BDMD.Check CVRX's competition here
BDMD vs BSGM Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, BDMD is priced at $1.77, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas BSGM's P/E ratio is -5.81. In terms of profitability, BDMD's ROE is -0.08%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, BDMD is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for BDMD.Check BSGM's competition here
BDMD vs INGN Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, INGN has a market cap of 189.5M. Regarding current trading prices, BDMD is priced at $1.77, while INGN trades at $6.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas INGN's P/E ratio is -8.09. In terms of profitability, BDMD's ROE is -0.08%, compared to INGN's ROE of -0.12%. Regarding short-term risk, BDMD is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check INGN's competition here
BDMD vs QTI Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, QTI has a market cap of 189.1M. Regarding current trading prices, BDMD is priced at $1.77, while QTI trades at $6.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas QTI's P/E ratio is -3.47. In terms of profitability, BDMD's ROE is -0.08%, compared to QTI's ROE of +3.64%. Regarding short-term risk, BDMD is more volatile compared to QTI. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check QTI's competition here
BDMD vs MDGS Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, BDMD is priced at $1.77, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas MDGS's P/E ratio is -0.27. In terms of profitability, BDMD's ROE is -0.08%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, BDMD is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for BDMD.Check MDGS's competition here
BDMD vs TLSI Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, TLSI has a market cap of 171.7M. Regarding current trading prices, BDMD is priced at $1.77, while TLSI trades at $4.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas TLSI's P/E ratio is -2.46. In terms of profitability, BDMD's ROE is -0.08%, compared to TLSI's ROE of +1.37%. Regarding short-term risk, BDMD is more volatile compared to TLSI. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check TLSI's competition here
BDMD vs SNWV Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, SNWV has a market cap of 166.4M. Regarding current trading prices, BDMD is priced at $1.77, while SNWV trades at $19.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas SNWV's P/E ratio is 47.22. In terms of profitability, BDMD's ROE is -0.08%, compared to SNWV's ROE of -1.42%. Regarding short-term risk, BDMD is more volatile compared to SNWV. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check SNWV's competition here
BDMD vs QIPT Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, BDMD is priced at $1.77, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas QIPT's P/E ratio is -15.87. In terms of profitability, BDMD's ROE is -0.08%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, BDMD is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check QIPT's competition here
BDMD vs APYX Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, APYX has a market cap of 162.1M. Regarding current trading prices, BDMD is priced at $1.77, while APYX trades at $3.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas APYX's P/E ratio is -14.35. In terms of profitability, BDMD's ROE is -0.08%, compared to APYX's ROE of -1.18%. Regarding short-term risk, BDMD is more volatile compared to APYX. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check APYX's competition here
BDMD vs NNOX Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, NNOX has a market cap of 151.4M. Regarding current trading prices, BDMD is priced at $1.77, while NNOX trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas NNOX's P/E ratio is -1.87. In terms of profitability, BDMD's ROE is -0.08%, compared to NNOX's ROE of -0.47%. Regarding short-term risk, BDMD is more volatile compared to NNOX. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check NNOX's competition here
BDMD vs QTRX Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, QTRX has a market cap of 151.1M. Regarding current trading prices, BDMD is priced at $1.77, while QTRX trades at $3.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas QTRX's P/E ratio is -1.28. In terms of profitability, BDMD's ROE is -0.08%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, BDMD is more volatile compared to QTRX. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check QTRX's competition here
BDMD vs LUCD Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, LUCD has a market cap of 130.9M. Regarding current trading prices, BDMD is priced at $1.77, while LUCD trades at $1.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas LUCD's P/E ratio is -1.86. In terms of profitability, BDMD's ROE is -0.08%, compared to LUCD's ROE of -5.91%. Regarding short-term risk, BDMD is more volatile compared to LUCD. This indicates potentially higher risk in terms of short-term price fluctuations for BDMD.Check LUCD's competition here
BDMD vs EDAP Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, EDAP has a market cap of 128.4M. Regarding current trading prices, BDMD is priced at $1.77, while EDAP trades at $3.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas EDAP's P/E ratio is -4.39. In terms of profitability, BDMD's ROE is -0.08%, compared to EDAP's ROE of -1.12%. Regarding short-term risk, BDMD is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for BDMD.Check EDAP's competition here
BDMD vs RCEL Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, RCEL has a market cap of 118.5M. Regarding current trading prices, BDMD is priced at $1.77, while RCEL trades at $4.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas RCEL's P/E ratio is -2.74. In terms of profitability, BDMD's ROE is -0.08%, compared to RCEL's ROE of +4.77%. Regarding short-term risk, BDMD is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for BDMD.Check RCEL's competition here
BDMD vs TMCI Comparison April 2026
BDMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDMD stands at 66.5M. In comparison, TMCI has a market cap of 118.2M. Regarding current trading prices, BDMD is priced at $1.77, while TMCI trades at $1.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDMD currently has a P/E ratio of -16.45, whereas TMCI's P/E ratio is -1.97. In terms of profitability, BDMD's ROE is -0.08%, compared to TMCI's ROE of -0.62%. Regarding short-term risk, BDMD is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for BDMD.Check TMCI's competition here